Cantor Fitzgerald raised the price target for the Aptose Biosciences Inc. (NASDAQ:APTO) stock to “an Overweight”. The rating was released on October 19, 2020. We previously noted in another research note published on September 22, 2020 by Alliance Global Partners that initiated the stock to a Buy for APTO stock. The research report from Maxim Group has initiated the stock to Buy, with a price target set at $16. The stock was reiterated by H.C. Wainwright, who disclosed in a research note on February 06, 2020, to Buy and set the price objective to $9. In their research brief published January 09, 2020, Piper Sandler analysts initiated the Aptose Biosciences Inc. stock to Overweight with a price target of $10.
Historical Earnings Surprises and Revenue Forecasts
Profit is the most critical financial performance measure. Every investor in a business is looking forward to the earnings report as stock price to increase when earnings exceed market expectations and progressively decrease when earnings do not meet expectations. The firm reported an earnings per share (EPS) of -$0.11 during the last quarter as opposed to a consensus estimate of -$0.15, which indicates the company beat its estimate by $0.04, which implies that the company surprised the market by 26.70%. It appears that the average earnings per share estimate for the current quarter (ending in Dec 2017) is -$0.14. This is an average of 3 analysts’ earnings, where the high earnings per share estimate is -$0.1 and the low earnings per share estimate is -$0.2.
The latest trade, Performances and Moving Averages give us the following Picture
The share price of Aptose Biosciences Inc. (NASDAQ:APTO) dipped -3.61% to close Thursday’s market session at $5.88, lower as compared to yesterday’s close. The stock price fluctuated between $5.00 and $6.03 throughout the trading session with the volume trading being 12055090 shares, which represented a significant variation when compared to the three months average volume of 4.05 million shares. The firm’s stock price fluctuated 54.33% within the last five trades and 41.35% within the last 30 trades, which was a significant change from the beginning of this year. Despite the fact that the share price increased 1.55% in the last 6 months and 38.68% was added to its value over the previous 3 months. APTO stock is trading at a margin of 48.13%, 38.83% and 13.63% apart from the 20-Day, 50-Day and 200-Day Simple Moving Average prices.
As of the close of trading, APTO deals in the Healthcare domain. The stock is trading -34.67 percent below its 52-week high and 73.45 percent above its 52-week low. For example, looking both at the price and the high and low measurements of 52 weeks will give you a clearer picture of the direction the price is heading. The firm’s Weighted Alpha is -9.2. A positive weighted alpha indicates the firm has done well over the course of the year, whereas one below 0 indicates that the firm has done poorly.
What Does Aptose Biosciences Inc.’s Profitability and Valuation Ratios Tell Us About the Stock?
The profit margin, also known as the revenue ratio or gross profit ratio, is an efficiency figure used to estimate the business’s profitability by comparing net income and sales. The higher the number, the more profits are generated for the company and vice versa.
The stock’s market cap achieved a total value of $519.67 million as of the last trading session. Market capitalization is the total value of all outstanding shares of a corporation and it is used to measure a company’s market value. The firm managed a Price-to-Book ratio of 3.92, which equates the market value of a stock with its book value.
Is Insider Trading a Real Thing?
Almost all investors and traders prefer to invest in shares controlled by the management of a corporation as a management company will be more likely to run the business itself and to never conduct things against the management’s desires and will always try to do what is best for their shareholders. Currently, 20.40 percent of Aptose Biosciences Inc. shares are owned by insiders, and 35.10 percent are held by financial institutions. Whitehead Warren, the Director at Aptose Biosciences Inc. (APTO) has sold 20,000 shares of firm on Dec 22 at a price of $4.06 against the total amount of $81200.0. In another inside trade, Chow Gregory K., Executive VP & CFO of Aptose Biosciences Inc. (NASDAQ:APTO) sold 126,668 shares of the firm on Jul 10 for a total worth of $0.77 million at a price of $6.05. An inside trade which took place on Jul 10, Chair, President & CEO of Aptose Biosciences Inc. Rice William G. sold 168,891 shares of firm against total price of $1.02 million at the cost of $6.05 per share.